Developer docs
API playgroundTry for free, no card

Search company profiles

Servier Australia

Full company profile

uuid00vnmvn

Namestring
Servier Australia
Legal namestring
Servier Laboratories (Aust.) Pty Ltd
Websiteurl
servier.com.au
Company typeenum
Private
Founded yearint
1966
Descriptiontext

Servier Australia, operating as Servier Laboratories (Aust.) Pty Ltd, is the Australian and New Zealand subsidiary of the France-headquartered Servier Group, an international pharmaceutical company governed by a non-profit foundation. Established in Australia in 1966 and headquartered in Hawthorn, Melbourne, the company develops, markets, and distributes prescription medicines across four therapeutic areas: Oncology, Neuroscience, Immuno-inflammation, and Cardio-metabolism. Its Australian product portfolio includes cardiovascular treatments (Coveram, Coralan), diabetes medications (Ardix Gliclazide MR), and the recently PBS-listed VORANIGO (vorasidenib), approved from 1 August 2026 as the first new treatment in over 20 years for Grade 2 IDH-mutant astrocytoma or oligodendroglioma.

The business operates a traditional pharma go-to-market: field sales representatives engage GPs and specialists directly, supported by the MyServier HCP portal (educational content, webinars, podcasts, BP monitoring resources), a medical information helpline (1800 153 590), and clinical workflow integrations (SQL queries for Best Practice medical software to identify hypertensive patients). Distribution flows through Australia's PBS for subsidized products and standard pharmacy networks post-prescription. Marketing spans the company website, LinkedIn, Facebook, and collaborative content partnerships such as the Confident Conversations YouTube series with TheCloudGP and youth charity 20Talk. Servier Australia also supports the National Hypertension Taskforce roadmap to reach 70% blood pressure control in Australia by 2030.

Revenue flows from one-time license sales of proprietary brand-name pharmaceuticals and generic products, with PBS reimbursement for listed products such as VORANIGO. The subsidiary employs 11-50 staff in Australia and operates a wholly-owned New Zealand subsidiary (Servier Laboratories NZ Limited, Auckland). Parent Group revenue was €4.9 billion in FY2021/2022, with 21,400 employees across 150+ countries and over 20% of brand-name revenue reinvested in R&D annually.

Short descriptiontext

Servier Australia is the Australian subsidiary of France's Servier Group, developing and distributing prescription medicines across Oncology, Neuroscience, Immuno-inflammation, and Cardio-metabolism to Australian and New Zealand patients via PBS reimbursement, field sales, and HCP digital engagement platforms.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMelbourne, Australia
HQ citystring
Melbourne
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
prescription pharmaceuticals, cardio-metabolic medicines, oncology therapeutics, neuroscience treatments, specialty pharmaceuticals
Industry3 codes
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Prescription Pharmaceuticals
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Brand-name pharmaceuticals
TypeOne Time License
Description

Servier develops and sells proprietary pharmaceutical products under its own brand across four therapeutic areas (Oncology, Neuroscience, Immuno-inflammation, Cardio-metabolism). Revenue from brand-name medicines was €3.7 billion for 2021/2022.

servier.com.au
2Generic pharmaceuticals
TypeOne Time License
Description

Servier also engages in generic drug activities, generating €1.2 billion in revenue for 2021/2022.

servier.com.au
3PBS-listed specialty oncology drug (VORANIGO)
TypeSubscription Recurring
Description

VORANIGO (vorasidenib) listed on Australia's Pharmaceutical Benefits Scheme from August 2026 for eligible patients with Grade 2 IDH-mutant astrocytama or oligodendroglioma, providing government-reimbursed access.

miragenews.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Supply Chain, Marketing or Sales, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Servier Australia develops, manufactures, and distributes proprietary prescription pharmaceutical medicines across four therapeutic areas: Oncology (notably VORANIGO/vorasidenib for rare brain cancers), Neuroscience (depression and anxiety treatments), Immuno-inflammation, and Cardio-metabolism (hypertension and cardiovascular products such as Coveram and Coralan, plus diabetes treatment Ardix Gliclazide MR). The company supports its medicines with healthcare professional education via the MyServier portal, patient education resources, and clinical tools such as downloadable SQL queries for Best Practice medical software. Products are distributed across Australia and New Zealand, with PBS-listed medicines receiving government reimbursement.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • VORANIGO is the first new treatment option in more than 20 years approved for Grade 2 IDH-mutant astrocytoma or oligodendroglioma
+2 more records
Product overview1 text field

Servier Australia offers a portfolio of pharmaceutical products across four therapeutic areas: Cardiovascular (including Coveram, Coralan), Diabetes (including Ardix Gliclazide MR), Neuropsychiatry, and Oncology. The company focuses on researching, developing, and fine-tuning innovative medicines, with recent addition of VORANIGO® (vorasidenib) for brain cancer treatment. Products are distributed across Australia and New Zealand, with recent PBS listing providing clinicians with targeted treatment options for rare brain cancers.

Product and service4 records
1VORANIGO (vorasidenib)
CategoryOncology Pharmaceutical
Description

Targeted oral therapy for adults and adolescents aged 12 and older with Grade 2 IDH-mutant astrocytoma or oligodendroglioma, a rare and previously underserved brain cancer. It is PBS-listed in Australia from August 2026 and is intended for prescription by oncology specialists.

2Ardix Gliclazide MR
CategoryDiabetes Pharmaceutical
Description

Gliclazide modified-release oral hypoglycaemic medication for the management of type 2 diabetes, prescribed by GPs and specialists in Australia.

3Coralan (ivabradine)
CategoryCardiovascular Pharmaceutical
Description

Ivabradine-based cardiovascular medication used for the treatment of chronic heart failure and stable angina, prescribed by cardiologists and GPs.

4Coveram (perindopril + amlodipine)
CategoryCardiovascular Pharmaceutical
Description

Fixed-dose combination of perindopril (ACE inhibitor) and amlodipine (calcium channel blocker) used for the treatment of hypertension and associated cardiovascular conditions, prescribed by GPs and specialists.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1National Hypertension Taskforce
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-10-09
Description

Servier Australia supports the National Hypertension Taskforce's mission to improve Australia's blood pressure control rate to 70% by 2030. The partnership involves co-development of patient infographics addressing common questions about hypertension, supporting healthcare professional education through MyServier, and participating in the three-pillar strategy focusing on prevention, detection, and effective treatment.

servier.com.au
2TheCloudGP
Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2024-07-10
Description

Servier Australia partnered with TheCloudGP (founded by Dr. Shiromi Wimalaguna) and 20Talk to produce the 'Confident Conversations: Talking Mental Health with Your GP' YouTube series. This collaboration provides practical mental health guidance for young Australians, addressing stigma around mental health consultations with general practitioners. The series includes video content on preparing for GP appointments, Mental Health Care Plan consultations, and maintaining momentum after appointments.

servier.com.au
Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2024-07-10
Description

20Talk, a youth charity focused on mental health for young adults aged 18-30, collaborated with Servier Australia and TheCloudGP on the Confident Conversations YouTube series. 20Talk's mission is to be the most relatable mental health charity of the 21st century, challenging the status quo and redefining mental health education. The partnership leverages 20Talk's youth engagement expertise with Servier's pharmaceutical resources.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Australia subsidiary of a privately-held international pharmaceutical group selling prescription medicines in pain, oncology, and consumer health, comparable as a privately-owned pharma distributor serving Australian GPs and specialists.

2Roche Products Australia
TypeBroad incumbent
Description

Australian arm of a global pharmaceutical leader with deep oncology and neuroscience franchises, providing a benchmark for specialty oncology launches such as Servier's VORANIGO.

TypeBroad incumbent
Description

Australian subsidiary of a diversified life sciences group with a strong cardiology, women's health, and specialty medicine portfolio, comparable as a broad incumbent competing in Servier's therapeutic categories.

TypeDirect peer
Description

Australia-headquartered specialty pharmaceutical company marketing branded and generic prescription medicines across multiple therapeutic areas, directly comparable as a domestically-distributed pharma operator with multi-indication portfolios.

5Sanofi Australia
TypeBroad incumbent
Description

Australian affiliate of a top-tier global pharmaceutical company with deep presence in cardiology, diabetes, and rare disease, overlapping with Servier's cardiometabolic and specialty care franchises.

TypeBroad incumbent
Description

Australian affiliate of the largest global pharmaceutical company, offering scale, portfolio breadth, and HCP engagement capabilities that set the competitive bar for Servier Australia's sales-led model.

TypeBroad incumbent
Description

Australian subsidiary of a global pharmaceutical company with leading cardiovascular, oncology, and respiratory portfolios that compete directly with Servier across its core therapy areas.

TypeDirect peer
Description

Australian subsidiary of a global specialty pharmaceutical group distributing branded and generic prescription products through pharmacy channels, comparable as a multi-indication pharma distributor with PBS exposure.

TypeBroad incumbent
Description

Australian operations of a global pharmaceutical major with significant cardiovascular, neuroscience, and oncology portfolios that intersect with Servier's four therapeutic areas.

10Boehringer Ingelheim Australia
TypeDirect peer
Description

Australian arm of a major privately-held global pharmaceutical company with strong cardiovascular, respiratory, and metabolic franchises, directly comparable as a foundation/family-controlled pharma competitor operating in Servier's core therapy areas.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Servier Australia

Prescription Pharmaceuticalsservier.com.au

Servier Australia is the Australian subsidiary of France's Servier Group, developing and distributing prescription medicines across Oncology, Neuroscience, Immuno-inflammation, and Cardio-metabolism to Australian and New Zealand patients via PBS reimbursement, field sales, and HCP digital engagement platforms.

What Servier Australia does

Servier Australia, operating as Servier Laboratories (Aust.) Pty Ltd, is the Australian and New Zealand subsidiary of the France-headquartered Servier Group, an international pharmaceutical company governed by a non-profit foundation. Established in Australia in 1966 and headquartered in Hawthorn, Melbourne, the company develops, markets, and distributes prescription medicines across four therapeutic areas: Oncology, Neuroscience, Immuno-inflammation, and Cardio-metabolism. Its Australian product portfolio includes cardiovascular treatments (Coveram, Coralan), diabetes medications (Ardix Gliclazide MR), and the recently PBS-listed VORANIGO (vorasidenib), approved from 1 August 2026 as the first new treatment in over 20 years for Grade 2 IDH-mutant astrocytoma or oligodendroglioma.

The business operates a traditional pharma go-to-market: field sales representatives engage GPs and specialists directly, supported by the MyServier HCP portal (educational content, webinars, podcasts, BP monitoring resources), a medical information helpline (1800 153 590), and clinical workflow integrations (SQL queries for Best Practice medical software to identify hypertensive patients). Distribution flows through Australia's PBS for subsidized products and standard pharmacy networks post-prescription. Marketing spans the company website, LinkedIn, Facebook, and collaborative content partnerships such as the Confident Conversations YouTube series with TheCloudGP and youth charity 20Talk. Servier Australia also supports the National Hypertension Taskforce roadmap to reach 70% blood pressure control in Australia by 2030.

Revenue flows from one-time license sales of proprietary brand-name pharmaceuticals and generic products, with PBS reimbursement for listed products such as VORANIGO. The subsidiary employs 11-50 staff in Australia and operates a wholly-owned New Zealand subsidiary (Servier Laboratories NZ Limited, Auckland). Parent Group revenue was €4.9 billion in FY2021/2022, with 21,400 employees across 150+ countries and over 20% of brand-name revenue reinvested in R&D annually.

Servier Australia firmographics

Firmographics
Name
Servier Australia
Legal name
Servier Laboratories (Aust.) Pty Ltd
Website
https://servier.com.au
Company type
Private
Founded year
1966
Operating status
Operating
Headcount range
11–50 employees
Short description
Servier Australia is the Australian subsidiary of France's Servier Group, developing and distributing prescription medicines across Oncology, Neuroscience, Immuno-inflammation, and Cardio-metabolism to Australian and New Zealand patients via PBS reimbursement, field sales, and HCP digital engagement platforms.
Ownership category
akta.pro rank

Servier Australia industry classification

Industry
Product category
Prescription Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Prescription pharmaceuticals
  • Cardio-metabolic medicines
  • Oncology therapeutics
  • Neuroscience treatments
  • Specialty pharmaceuticals

Where Servier Australia is headquartered

Location

Headquarters

HQ city
Melbourne
HQ country
Australia
HQ region
Oceania

Offices3 records

Markets served

Servier Australia business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Marketing or Sales, Personnel, Operations

Revenue model

  1. Brand-name pharmaceuticals: Servier develops and sells proprietary pharmaceutical products under its own brand across four therapeutic areas (Oncology, Neuroscience, Immuno-inflammation, Cardio-metabolism). Revenue from brand-name medicines was €3.7 billion for 2021/2022.
  2. Generic pharmaceuticals: Servier also engages in generic drug activities, generating €1.2 billion in revenue for 2021/2022.
  3. PBS-listed specialty oncology drug (VORANIGO): VORANIGO (vorasidenib) listed on Australia's Pharmaceutical Benefits Scheme from August 2026 for eligible patients with Grade 2 IDH-mutant astrocytama or oligodendroglioma, providing government-reimbursed access.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels8 records

Servier Australia product offering

Product offering

Core offering

Servier Australia develops, manufactures, and distributes proprietary prescription pharmaceutical medicines across four therapeutic areas: Oncology (notably VORANIGO/vorasidenib for rare brain cancers), Neuroscience (depression and anxiety treatments), Immuno-inflammation, and Cardio-metabolism (hypertension and cardiovascular products such as Coveram and Coralan, plus diabetes treatment Ardix Gliclazide MR). The company supports its medicines with healthcare professional education via the MyServier portal, patient education resources, and clinical tools such as downloadable SQL queries for Best Practice medical software. Products are distributed across Australia and New Zealand, with PBS-listed medicines receiving government reimbursement.

Product overview

Servier Australia offers a portfolio of pharmaceutical products across four therapeutic areas: Cardiovascular (including Coveram, Coralan), Diabetes (including Ardix Gliclazide MR), Neuropsychiatry, and Oncology. The company focuses on researching, developing, and fine-tuning innovative medicines, with recent addition of VORANIGO® (vorasidenib) for brain cancer treatment. Products are distributed across Australia and New Zealand, with recent PBS listing providing clinicians with targeted treatment options for rare brain cancers.

Differentiator

Problem solved

Functional benefit

Products and services

  • VORANIGO (vorasidenib) Targeted oral therapy for adults and adolescents aged 12 and older with Grade 2 IDH-mutant astrocytoma or oligodendroglioma, a rare and previously underserved brain cancer. It is PBS-listed in Australia from August 2026 and is intended for prescription by oncology specialists.
  • Ardix Gliclazide MR Gliclazide modified-release oral hypoglycaemic medication for the management of type 2 diabetes, prescribed by GPs and specialists in Australia.
  • Coralan (ivabradine) Ivabradine-based cardiovascular medication used for the treatment of chronic heart failure and stable angina, prescribed by cardiologists and GPs.
  • Coveram (perindopril + amlodipine) Fixed-dose combination of perindopril (ACE inhibitor) and amlodipine (calcium channel blocker) used for the treatment of hypertension and associated cardiovascular conditions, prescribed by GPs and specialists.

Quantifiable outcome

  • VORANIGO is the first new treatment option in more than 20 years approved for Grade 2 IDH-mutant astrocytoma or oligodendroglioma
  • +2 more outcomes

Companies that use Servier Australia

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Servier Australia technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature3 records

Servier Australia partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • National Hypertension TaskforcecoreStrategic or Co-development Partner · 9 October 2024Servier Australia supports the National Hypertension Taskforce's mission to improve Australia's blood pressure control rate to 70% by 2030. The partnership involves co-development of patient infographics addressing common questions about hypertension, supporting healthcare professional education through MyServier, and participating in the three-pillar strategy focusing on prevention, detection, and effective treatment.
  • TheCloudGPcoreGTM or Marketing Partner · 10 July 2024Servier Australia partnered with TheCloudGP (founded by Dr. Shiromi Wimalaguna) and 20Talk to produce the 'Confident Conversations: Talking Mental Health with Your GP' YouTube series. This collaboration provides practical mental health guidance for young Australians, addressing stigma around mental health consultations with general practitioners. The series includes video content on preparing for GP appointments, Mental Health Care Plan consultations, and maintaining momentum after appointments.
  • 20TalkcoreGTM or Marketing Partner · 10 July 202420Talk, a youth charity focused on mental health for young adults aged 18-30, collaborated with Servier Australia and TheCloudGP on the Confident Conversations YouTube series. 20Talk's mission is to be the most relatable mental health charity of the 21st century, challenging the status quo and redefining mental health education. The partnership leverages 20Talk's youth engagement expertise with Servier's pharmaceutical resources.

Scale indicators9 records

Recent moves5 records

Expansion highlights5 records

Servier Australia competitors and assessment

Company assessment

Direct peers

  • Mundipharma Australia: Australia subsidiary of a privately-held international pharmaceutical group selling prescription medicines in pain, oncology, and consumer health, comparable as a privately-owned pharma distributor serving Australian GPs and specialists.
  • Mayne Pharma Group: Australia-headquartered specialty pharmaceutical company marketing branded and generic prescription medicines across multiple therapeutic areas, directly comparable as a domestically-distributed pharma operator with multi-indication portfolios.
  • Aspen Pharmacare Australia: Australian subsidiary of a global specialty pharmaceutical group distributing branded and generic prescription products through pharmacy channels, comparable as a multi-indication pharma distributor with PBS exposure.
  • Boehringer Ingelheim Australia: Australian arm of a major privately-held global pharmaceutical company with strong cardiovascular, respiratory, and metabolic franchises, directly comparable as a foundation/family-controlled pharma competitor operating in Servier's core therapy areas.

Broad incumbents

  • Roche Products Australia: Australian arm of a global pharmaceutical leader with deep oncology and neuroscience franchises, providing a benchmark for specialty oncology launches such as Servier's VORANIGO.
  • Bayer Australia: Australian subsidiary of a diversified life sciences group with a strong cardiology, women's health, and specialty medicine portfolio, comparable as a broad incumbent competing in Servier's therapeutic categories.
  • Sanofi Australia: Australian affiliate of a top-tier global pharmaceutical company with deep presence in cardiology, diabetes, and rare disease, overlapping with Servier's cardiometabolic and specialty care franchises.
  • Pfizer Australia: Australian affiliate of the largest global pharmaceutical company, offering scale, portfolio breadth, and HCP engagement capabilities that set the competitive bar for Servier Australia's sales-led model.
  • AstraZeneca Australia: Australian subsidiary of a global pharmaceutical company with leading cardiovascular, oncology, and respiratory portfolios that compete directly with Servier across its core therapy areas.
  • Novartis Australia: Australian operations of a global pharmaceutical major with significant cardiovascular, neuroscience, and oncology portfolios that intersect with Servier's four therapeutic areas.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Servier Australia social profiles

Digital presence

Servier Australia financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Servier Australia leadership team

Management profile

Number of profiles

Servier Australia subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Servier Australia funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Servier Australia M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Servier Australia

What does Servier Australia do?

Servier Australia develops, manufactures, and distributes proprietary prescription pharmaceutical medicines across four therapeutic areas: Oncology (notably VORANIGO/vorasidenib for rare brain cancers), Neuroscience (depression and anxiety treatments), Immuno-inflammation, and Cardio-metabolism (hypertension and cardiovascular products such as Coveram and Coralan, plus diabetes treatment Ardix Gliclazide MR). The company supports its medicines with healthcare professional education via the MyServier portal, patient education resources, and clinical tools such as downloadable SQL queries for Best Practice medical software. Products are distributed across Australia and New Zealand, with PBS-listed medicines receiving government reimbursement.

Is Servier Australia a public or private company?

Servier Australia is a private company. It is classified as corporate owned and is currently operating.

When was Servier Australia founded?

Servier Australia was founded in 1966. It employs 11 to 50 people.

Where is Servier Australia based?

Servier Australia is headquartered in Melbourne, Australia, in the Oceania region.

How does Servier Australia make money?

Three revenue lines are on record. Brand-name pharmaceuticals are the primary driver. The others are generic pharmaceuticals and PBS-listed specialty oncology drug (VORANIGO).

Who are Servier Australia's main competitors?

Direct peers on record are Mundipharma Australia, Mayne Pharma Group, Aspen Pharmacare Australia and Boehringer Ingelheim Australia. Broad incumbents are Roche Products Australia, Bayer Australia, Sanofi Australia, Pfizer Australia, AstraZeneca Australia and Novartis Australia.

Does Servier Australia have an API?

No public API is recorded for Servier Australia.

What industry is Servier Australia in?

Servier Australia's product category is Prescription Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity), with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals